There is long-term (trophic) purinergic signalling involving cell proliferation, differentiation, motility and death in the development and regeneration of most systems of the body, in addition to fast purinergic signalling in neurotransmission, neuromodulation and secretion. It is not always easy to distinguish between short-and long-term signalling. For example, adenosine triphosphate (ATP) can sometimes act as a short-term trigger for long-term trophic events that become evident days or even weeks after the original challenge. Examples of short-term purinergic signalling during sympathetic, parasympathetic and enteric neuromuscular transmission and in synaptic transmission in ganglia and in the central nervous system are described, as well as in neuromodulation and secretion. Long-term trophic signalling is described in the immune/defence system, stratified epithelia in visceral organs and skin, embryological development, bone formation and resorption and in cancer. It is likely that the increase in intracellular Ca 2þ in response to both P2X and P2Y purinoceptor activation participates in many short-and long-term physiological effects. This article is part of the themed issue 'Evolution brings Ca 2þ and ATP together to control life and death'.
Introduction
The proposal that purine nucleotides are extracellular signalling molecules, as well as an intracellular energy source, was first reported by Drury & SzentGyö rgyi [1] . Then in 1970, adenosine 5 0 -triphosphate (ATP) was shown to be a transmitter in autonomic neuromuscular transmission [2] and in a later review the term 'purinergic' signalling was introduced [3] . This concept was not accepted by many for the next 20 years. Separate purinergic receptor families, P1 (adenosine) and P2 (ATP/adenosine 5 0 -diphosphate (ADP)) were described in 1978 [4] , but the turning point in acceptance of purinergic signalling came after the receptors for purines and pyrimidines were cloned and characterized in the early 1990s [5] . Four P1 receptor subtypes (A 1 , A 2A , A 2B , A 3 ), seven P2X ion channel receptors (P2X 1 -7 ) and eight G-protein-coupled receptors (P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 , P2Y 14 ) are currently recognized [6] . Activation of P2 receptors leads to increase in intracellular Ca 2þ : from extracellular sources for P2X receptors and from intracellular sites for P2Y receptors. Perhaps because of their ancient origin, the array of purinoceptor subtypes has a unique property of being extraordinarily widely distributed throughout living cells and tissues [7] . In contrast to all other chemical transmitters, which are, as a rule, segregated to certain cell types and certain functions, the receptors for purines and pyrimidines are found everywhere, and it is almost impossible to find a cell without sensitivity to ATP and its analogues. There has been a rapid expansion of the field since 1995 [8, 9] .
parasympathetic nerves in the urinary bladder [10] . Shortterm purinergic signalling was demonstrated when ATP was identified as a cotransmitter with noradrenalin in sympathetic nerves in the taenia coli [11] , cat nictitating membrane [12] , vas deferens [13, 14] and in blood vessels [15, 16] . ATP is also a cotransmitter with acetylcholine in motor nerves supplying developing skeletal muscle [17] , bladder [18] and carotid body [19] and in sensory-motor nerves with substance P and calcitonin gene-related peptide [20] . Later ATP was shown to be a cotransmitter, mediating short-term purinergic signalling, in neurons in the central nervous system (CNS) [8, 21, 22] . The involvement of shortterm purinergic signalling in the control of vascular tone is illustrated in figure 1 . Purinergic synaptic transmission between nerves was shown in the coeliac ganglion [24, 25] and the medial habenula in the brain [26] . ATP released during synaptic transmission can activate astrocyte receptors, which in turn initiate Ca 2þ signals and propagate Ca 2þ waves in the astroglial networks via the activation of P2Y receptors and the diffusion of inositol trisphosphate (IP 3 ) through the gap junctions [27] . Ionotropic P2X receptors are responsible for rapid astrocytic signalling, whereas metabotropic P2Y receptors mediate long-term effects [28] . Short-term signalling involved in prejunctional neuromodulation via both P1 and P2 receptors was also recognized in both peripheral [20, 29, 30] and CNSs [31, 32] . Purinoceptors are extensively present in the CNS, where they mediate neuronal excitability and they are important for signalling in neuronal -glial circuitry, being an important gliotransmitter [8, 33, 34] .
Purinoceptors are present in all peripheral tissues, being involved in short-term as well as long-term regulation of different functions, including neuromuscular and synaptic transmission and secretion in gut [35] , and secretion in kidneys [36] , liver [37] and reproductive systems [38] . In vascular [16] and respiratory systems, ATP mediates reflex activities via activation of sensory nerves [39] . Activation of purinoceptors can mediate rapid responses in the immunological system [40] , in blood cells [41] , skin [42] , bones and muscles [43] , urinary tract [44] and heart [45] . Short-term purinergic signalling also takes place in secretion from endocrine [46] and nonendocrine cells [35] . P2X 3 3. Long-term (trophic) purinergic signalling ATP and it analogues are involved in tissue remodelling in response to injury and play a key role in the regulation of subsequent repair and regeneration [48] . Stimulation of purinoceptors triggers astrogliosis, the generalized response of astrocytes to brain damage, involving cell proliferation and remodelling of the neural circuitry [49, 50] . Reactive astrogliosis is instrumental for both the formation of scar and limitation of brain-damaged area (through anisomorphic astrogliosis), as well as for the post-insult remodelling and recovery of neural function (by isomorphic astrogliosis). The initial events in the responses of astroglia to purinergic signalling are instrumental for glial Ca 2þ excitability or can initiate long-term effects [51] . For reactive astrogliosis, not only was increase in intracellular calcium absolutely necessary, but ATP was also shown to be one of the key factors involved in its initiation via the activation of P2Y G-proteincoupled receptors linked to phospholipase C and IP 3 [52] . These trophic/astrogliotic proliferative effects of P2 agonists were found both in vitro, in glial cultures, and in vivo, in nucleus accumbens of rats [53 -56] . P2X receptors mediate long-term potentiation in the hippocampus [57] . Activation of P2X receptors can have multiple effects on synaptic plasticity, either inhibiting or facilitating the long-term changes of synaptic strength depending on the physiological context [58] . Long-term purinergic signalling also occurs in chronic inflammation and neuropathic pain [59] .
(a) Embryological development P2 receptor subtypes appear transiently during both embryological and postnatal development, suggesting that ATP is involved in the sequential proliferation, differentiation, motility and death of cells during the complex events involved [8, 60, 61] . For example, in Xenopus embryos a novel P2Y 8 receptor was cloned and shown to be transiently expressed in the neural plate and tube from stages 13 to 18 and again at stage 28, when secondary neurulation occurs in the tail bud [62] . Transient expression of P2Y 1 receptors in the limb buds of chick embryos mediates rapid cell proliferation [63] . During postnatal development of cerebellum [64] and skeletal muscle [65] changes in expression of P2X receptor subtypes have been described. Purinergic signalling in development is likely to involve cross-talk between several other signalling pathways, including growth factors, cytokines and extracellular matrix components [61] . During early development of the myotube P2X 5 receptors were present, followed by P2X 6 receptor expression, and then P2X 2 receptors were expressed during the development of the neuromuscular 0 -triphosphate (UTP) through ecto-nucleotidases. All three nucleotides can function separately on specific P2 receptor subtypes, as indicated by the colour coding. ATP is a universal agonist, whereas UTP is only active at the P2Y 2 receptor and ADP is only active at the P2Y 1 receptor. ADP acting on P2Y 1 receptors seems to stimulate both the formation (i.e. fusion) of osteoclasts from haematopoietic precursors and the resorptive activity of mature osteoclasts. For the latter, a synergistic action of ATP and protons by the P2X 2 receptor has been proposed. ADP could also stimulate resorption indirectly through actions on osteoclasts, which in turn release pro-resorptive factors (e.g. receptor activator of nuclear factor kB ligand, RANKL). ATP at high concentrations might facilitate fusion of osteoclast progenitors through P2X 7 receptor pore formation or induce cell death of mature osteoclasts through P2X 7 receptors. In osteoblasts, ATP, through P2X 5 receptors, might enhance proliferation and/or differentiation. By contrast, UTP, through P2Y 2 receptors, is a strong inhibitor of bone formation by osteoblasts. For some receptors (e.g. P2X 4 and P2Y 2 receptors on osteoclasts or P2X 2 receptors on osteoblasts), evidence for expression has been found but their role is still unclear. (Reproduced from [68] , with permission.) rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 371: 20150422 junction. ATP-evoked Ca 2þ transients in the chicken retina were the strongest as early as E3, but were drastically reduced at E11-13.5 [66] . Similar mechanisms are involved in adult neurogenesis [67] .
(b) Bone formation and resorption
Osteoclast activity and bone resorption are activated by ADP via P2Y 1 receptors, whereas ATP and uridine 5 0 -triphosphate (UTP) signalling via P2Y 2 receptors in osteoblasts inhibits bone growth and mineralization (figure 2) [43, 69, 70] . P2X 7 receptors have trophic regulatory roles in bone formation and resorption [71, 72] . Osteoblasts activated by P2X 7 receptors show enhanced differentiation and bone formation [73] , whereas P2X 7 receptor activation of osteoclasts evokes apoptosis and bone resorption [74 -76] . . This suggests that the increase in vascular smooth muscle and endothelial cells in both atherosclerosis and hypertension may be mediated by the trophic actions of purines and pyrimidines released from nerves and endothelial cells [77] [78] [79] and in post-angioplasty restenosis [80] . P2Y 4 receptors appear to be regulators of angiogenesis [81] . DNA synthesis and migration of vascular endothelial cells in vasa vasorum is increased by ATP in diseased pulmonary vessels [82] . Microvascular disease is characterized by an increased wall -lumen ratio in diabetic patients. This is probably because of an increase in vascular smooth muscle cells leading to higher rates of restenosis after angioplasty. Release of ATP, induced by high glucose, stimulates vascular smooth muscle cell growth via P2Y receptors [83] . An unusual type of long-term purinergic signalling is the evidence that at a critical concentration ATP, acting on both erythrocytes [84] and endothelial cells [85] , leads to increase in ATP release into the circulating blood for several hours.
(d) Skin
Stratified squamous epithelia in rat skin as well as cornea, oesophagus, soft palate, vagina and tongue showed heavy immunostaining of the P2X 5 receptor associated with cell differentiation in the spinous and granular cell layers, but not in basal cuboidal outer layers. There was heavy immunostaining of P2X 7 receptors in the outer layer, associated with apoptotic cell death [86] . There is rapid turnover of the epithelium of the small intestine. P2X 5 Figure 4 . Double-labelling of P2Y 1 and P2Y 2 receptors with markers of proliferation shows colocalization within a subpopulation of basal and parabasal keratinocytes. Double-labelling of P2X 5 receptors with markers of differentiated keratinocytes shows colocalization within the stratum spinosum, and double-labelling of P2X 7 receptors with markers of apoptosis in human leg skin shows colocalization within the stratum corneum. (a) Ki-67 immunolabelling (a marker for proliferation) stained the nuclei (green) of a subpopulation of keratinocytes in the basal and parabasal layers of the epidermis. P2Y 1 receptor immunostaining (red) was found in the basal layer on cells also staining for Ki-67. (b) PCNA immunolabelling (a marker for proliferation) stained the nuclei (green) of a subpopulation of keratinocytes. These nuclei were often distributed in clusters and found in the basal and parabasal layers of the epidermis. P2Y 2 receptor immunostaining (red) was also expressed in basal and parabasal epidermal cells. (c) P2X 5 receptor immunostaining (red) showed overlap (yellow) with cytokeratin K10 (green), an early marker of keratinocyte differentiation. P2X 5 receptors were present in the basal layer of the epidermis up to the midgranular layer. Cytokeratin K10 was distributed in most suprabasal keratinocytes. The stratum basale stained only for P2X 5 receptors, indicating that no differentiation was taking place in these cells. The colocalization of P2X 5 receptors and cytokeratin K10 appeared mainly in the cytoplasm of differentiating cells within the stratum spinosum and partly in the stratum granulosum. Note that the stratum corneum also stained for cytokeratin K10, which labelled differentiated keratinocytes, even in dying cells. (d ) P2X 5 receptor immunostaining (red) showed overlap (yellow) with involucrin (green). P2X 5 receptors were present in the basal layer of the epidermis up to the midgranular layer. Note that the pattern of staining with involucrin was similar to that seen with cytokeratin K10, except that cells from the stratum basale up to the midstratum spinosum were not labelled with involucrin, which is a late marker of keratinocyte differentiation. (e) TUNEL (green) labelled the nuclei of cells at the uppermost level of the stratum granulosum and P2X 7 antibody (red) mainly stained cell fragments within the stratum corneum. (f ) Anti-caspase-3 (green) colocalized with areas of P2X 7 receptor immunostaining (red) both at the junction of the stratum granulosum and within the stratum corneum. Areas of colocalization were yellow. Note that the differentiating keratinocytes in the upper stratum granulosum were also positive for anti-caspase-3. Scale bars (a - 7 , P2Y 1 and P2Y 2 receptor subtype expression was studied in healthy human epidermal keratinocytes in relation to markers for proliferation (PCNA and Ki-67), differentiation (cytokeratin KIO and involucrin) and apoptosis (TUNEL and anticaspase-3) [88] . P2Y 1 and P2Y 2 receptors were immunoreactive in basal and parabasal keratinocytes. Expression of P2X 5 receptors within the stratum spinosum and P2X 7 receptors in the stratum corneum was associated with cell differentiation (and subsequent anti-proliferation) and apoptotic cell death, respectively (figure 4). Functional experiments on cultured keratinocytes showed an increase in cell numbers in response to the P2Y 1 receptor agonist 2-methylthio ADP and the P2Y 2 receptor agonist UTP. By contrast, there was a significant decrease in cell numbers with the P2X 5 receptor agonist ATPgS and the P2X 7 receptor agonist 2 0 (3 0 )-O-(4-benzoylbenzoyl) ATP. It was also shown that P2Y 1 receptors in the basal layer of the developing human fetal epidermis were associated with proliferation [89] . P2X 5 receptors, predominantly in the basal and intermediate layers, were associated with differentiation, while P2X 7 receptors in the periderm were associated with apoptotic cell death.
Purinergic signalling is involved in wound healing. In regenerating epidermis of denervated wounds, P2Y 1 receptor expression was increased in keratinocytes, while P2Y 2 receptor expression was decreased [90] . Nerve growth factor (NGF) treatment of denervated wounds reduced expression of P2Y 1 receptors and increased expression of P2Y 2 receptors. NGF treatment enhanced both P2X 5 and P2Y 1 receptors in keratinocytes in innervated wounds. In all experimental wound healing processes, P2X 7 receptors were absent.
Human anagen hair follicles express P2Y 1 , P2Y 2 and P2X 5 receptors [91] . P2Y 1 receptors were present in proliferating cells in the outer root sheath and bulb, while P2X 5 receptors were associated with differentiation of the inner and outer root sheaths and medulla. P2Y 2 receptors were found in cells at the edge of the cortex/medulla, while P2X 7 receptors were not present.
(e) Cancer
Analysis of the purinergic receptor subtypes involved in the development of tumours in the prostate [92] , bladder [93] , melanoma [94, 95] , breast [96] [97] [98] and other organs has been described [99, 100] . P2Y 1 and P2Y 2 receptors were expressed and involved in cell proliferation; P2X 5 receptors were involved in differentiation (and were therefore antiproliferative), while P2X 7 receptors were involved in cell death in many tumours (figure 5). However, P2X 7 receptors have been shown to mediate both proliferation of cancer cells and apoptotic cell death [101] . It may be that low concentrations of released ATP promote proliferation, while high concentrations lead to cell death. In human melanomas, functional P2X 7 receptors are expressed that mediate apoptosis [94] , while P2Y 1 and P2Y 2 receptor agonists cause a decrease and increase in cell numbers, respectively [95] . In human squamous cell carcinoma, P2Y 2 , P2X 5 and P2X 7 receptors appear to be associated with proliferation, differentiation and cell death, respectively [102] .
Using the HT-1376 high grade bladder cancer cell line, P2X 5 and P2Y 11 receptors mediated the anti-neoplastic effects of ATP, while P2X 7 receptors mediated apoptotic cell death [93] . Cell lines of hormone-refractory prostate cancer showed similar results [103] . ATP reduced the in vivo 4. Second messenger mechanisms and transcription factors involved in short-and long-term purinergic signalling
The second messenger mechanisms involved in short-term purinergic signalling have been analysed in a number of studies for P2X ion channel receptors [105 -109] . Occupation of both P2X and P2Y receptors leads to an increase in intracellular Ca 2þ , P2X receptors from extracellular sources and P2Y receptors from intracellular sources [5, 110] . It was shown that extracellular ATP activates the P2X channel trimeric structure by binding the three intersubunit-binding sites, which leads to conformational rearrangements that are transferred to transmembrane helices linked to ATPbinding domains by b strands [111] . Coupling of the P2Y receptor subtypes to specific G proteins was initially inferred from indirect evidence from movement of intracellular levels of IP 3 , calcium, cyclic AMP (cAMP) and determination of pertussis toxin sensitivity. Direct evidence followed by measuring the effect of ADP and GTP hydrolysis in vesicles reconstituted with P2Y 1 and either Ga q b 1 g 2 or Ga 11 b 1 g 2 [112] . G-protein-coupled P2Y receptors also modulate the activity of voltage-gated ion channels in the cell membrane through the activity of activated G proteins (see [113] for a detailed analysis). The transcription factors involved in long-term trophic signalling are more complex, as indicated in figure 6 . A role for calcium influx in cell proliferation has been proposed [114] . External calcium concentration is important for calcium channel function and it also regulates calcium sensing receptor activity. Activation of the P2Y 11 receptor by ATP, for example, leads to a rise in cAMP and in IP 3 and cytosolic calcium, whereas activation by UTP was shown to produce calcium mobilization without IP 3 or cAMP increase [115] . Figure 6 . Schematic overview of purinergic signalling mechanisms that regulate long-term, trophic effects. Extracellular nucleotides and nucleosides bind to purinergic receptors coupled to signal transducing effector molecules. Activation of the effectors leads to generation of second messengers and/or stimulation of protein kinases that regulate expression of genes needed for long-term, trophic actions. In some cases, P2X receptors such as P2X 7 are also coupled to protein kinase cascades and can mediate proliferation and apoptosis. Cell-specific and/or receptor subtype-specific differences are likely to account for variations in signalling pathways and functional outcomes. It should be noted that the list of elements is not meant to be all-inclusive. Other protein kinases, e.g. MEK, PI3 K, are upstream of the listed kinases involved in purinergic signalling while others are downstream, e.g. p70S6 K. In addition, dashed arrows indicate that not all listed elements are activated by the upstream component, e.g. not all P1 receptors are coupled to all listed effectors. AC, adenylyl cyclase; AP-1, activator protein-1; CaMK, calciumcalmodulin protein kinase; CREB, cyclic AMP response element binding protein; DG, diacylglycerol; GSK, glycogen synthase kinase; IP 3 , inositol trisphosphate; MAPKs, mitogen-activated protein kinases (including extracellular signal regulated protein kinase (ERK), p38 MAPK and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK)); MEK, MAPK/ERK kinase; NO, nitrous oxide; PG, prostaglandin; PI3 K, phosphoinositide 3-kinase; PI-PLC, phosphatidylinositol-specific phospholipase C; PKA, protein kinase A; PKC, protein kinase C; PLD, phospholipase D; PLA, phospholipase A; STAT3, signal transducer and activator of transcription-3. (Reproduced from [8] , with permission.) rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 371: 20150422
Conclusion
Trimeric P2X ion channel receptors largely mediate shortterm purinergic signalling, although there are examples of P2X receptor-mediated long-term signalling. P1 and P2Y G-protein-coupled receptors are predominantly involved in long-term (trophic) purinergic signalling, but there are also examples of mediation of short-term events. Examples of both types of purinergic signalling are explored and the intracellular translational mechanisms involved discussed.
Knowledge of the underlying mechanisms involved in both short-and long-term purinoceptor-mediated signalling will help in the development of purinergic drugs for therapeutic purposes.
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